title: Transition considerations for extended half-life factor products.
authors: Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
authors: S E
authors: SE
authors: Croteau
authors: Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
authors: E J
authors: EJ
authors: Neufeld
mesh_terms: D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics*; D005164:Factor IX / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics; D005169:Factor VIII / Q000008:administration & dosage / Q000191:economics / Q000493:pharmacokinetics; D006207:Half-Life; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans
chemical_list: D001779:Blood Coagulation Factors; D005169:Factor VIII; D005164:Factor IX